Open-label Adjunctive Zonisamide for Bipolar Disorder
This study has been terminated.
First Posted: October 10, 2002
Last Update Posted: December 14, 2015
Information provided by:
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Elan Pharmaceuticals:
Contacts and Locations
No Contacts or Locations Provided